Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma
نویسندگان
چکیده
منابع مشابه
Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma
OBJECTIVE The purpose of this study was to evaluate the clinical efficacy of continuous low-dose temozolomide (TMZ) chemotherapy for recurrent and TMZ-refractory glioblastoma multiforme (GBM) and to study the relationship between its efficacy and microvessel density within the tumor. METHODS Thirty patients who had recurrent GBM following Stupp's regimen received TMZ daily at 50 mg/m(2)/day u...
متن کاملContinuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients
In glioblastoma multiforme (GBM), both temozolomide (TMZ) and cisplatin are very active at various toxic levels. Previous studies demonstrated that cisplatin with the standard regimen of TMZ is active in patients suffering from recurrent GBM, generating a moderate level of toxicity. Also, continuous dose-intense TMZ is a helpful therapy for patients with recurrent GBM. We have conducted a resea...
متن کاملPhase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
The prognosis for patients with recurrent glioblastomas (GBMs) is dismal, with a median survival of 3-6 months. We performed a phase II trial of low-dose continuous (metronomic) treatment using temozolomide (TMZ) for recurrent GBMs. TMZ-refractory patients with GBM who experienced disease recurrence or progression during or after the cyclic treatment schedule of TMZ after surgery and standard r...
متن کاملAre we done with dose-intense temozolomide in recurrent glioblastoma?
In this month’s issue of Neuro-Oncology, Han et al present another sobering result of dose-dense chemotherapy in a series of 40 recurrent glioblastoma patients failing chemo-irradiation with temozolomide (TMZ). In a well-designed trial the investigators avoided patients with pseudoprogression by not excluding patients relapsing within three months from the end of radiotherapy (RT), and also too...
متن کاملPhase II study of dose-intense temozolomide in recurrent glioblastoma.
2038 Background: Most GBM patients relapse within 1 year from diagnosis. Among patients who progress on standard temozolomide, the optimal therapy is unknown. Resistance to temozolomide is partially mediated by the DNA repair enzyme, O6-methylguanine-DNA methyltransferase (MGMT). Since MGMT may be depleted by prolonged temozolomide administration, dose-intense schedules may overcome resistance ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Korean Neurosurgical Society
سال: 2015
ISSN: 2005-3711,1598-7876
DOI: 10.3340/jkns.2015.58.5.426